TCR characterization during immunomodulatory treatment is both feasible and informative, and may enable monitoring of pathogenic or protective T cell clones following HSCT and cellular therapies. PubMed, J Clin Invest. 2014 Feb 17. (Also see: Multiple Sclerosis and Stem Cell Transplantation)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.